Immunis, Inc.
PrivateLast Round
Seed Round
Jun 15, 2026
Est. Valuation
$30M
Total Funding Raised
$35.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Immunis, Inc. is a biotechnology company that develops multi-active biologics derived from stem cell secretomes to address age-related diseases and immune dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunis, Inc. Comparables
Compare Immunis, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 84% | |
| Remedy Cell Ltd. | 76% | |
| Direct Biologics | 72% |
Immunis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 15, 2026 | ||||
| Grant | May 12, 2025 | ||||
| Series A Extension | Jan 11, 2025 | ||||
| Series A | Aug 3, 2022 |
Immunis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A Extension, Series A |
| BOLD Capital Partners | Series A Extension |
| X PRIZE Foundation | Grant |
| Continuum Health Ventures | Series A Extension, Series A |
| LifeSpan Vision Ventures | Series A Extension |
| JLS Fund | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 34% MoM.
- Jul 15, 2026
Grew 22% QoQ, from 18 to 22 employees.
Immunis, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immunis, Inc.'s valuation, stock price, and market status.
Is Immunis, Inc. a public or private company?
Immunis, Inc. is a private company.
What is the current stock price of Immunis, Inc.?
Immunis, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Immunis, Inc. worth (valuation)?
Valuation information for Immunis, Inc. is not publicly available.
Can I buy Immunis, Inc. stock?
Immunis, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immunis, Inc.'s last funding round?
Immunis, Inc.'s most recent funding round was Seed Round on June 15, 2026.
Who are the main investors in Immunis, Inc.?
Key investors in Immunis, Inc. include Remiges Ventures.
Will Immunis, Inc. IPO soon?
No public IPO plans have been announced for Immunis, Inc..
How can I track Immunis, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunis, Inc.'s secondary market activity and sign up for updates.